⚠️ Not investment advice. This is a quantitative research tool; every decision is the user's own responsibility. Past performance does not guarantee future results.⚠️ Not investment advice. Past performance does not guarantee future results.
⚠️ Not investment advice. Past performance does not guarantee future results.
🔓 Sign up freeSee the full rankingSign in with Google
← Back to the full ranking · All companies

Reckitt Benckiser RKT.L

United Kingdom Consumer Defensive
6.1/10
AI Analyst score
49.48 GBP
Last price at analysis date · analyst target 62.39 (+26.1%)
🛒 Where to buy RKT.LPartner brokers · UK (LSE) · sample 200.00 € orderUK (LSE)
Meridian is paid by these brokers at no extra cost to you; this is not investment advice. Public fee schedules · commission and FX, taxes excluded · Compare all 22 brokers by real cost →
No partner-broker fees for this market yet · Broker cost comparison →
🟡 HOLD — Hold; quality and valuation provide support, but lack of growth and leverage limit upside potential in the short term.

Reckitt Benckiser is a British multinational consumer goods company that manufactures and sells cleaning, health, and nutrition products under brands such as Lysol, Durex, and Nurofen, with a business model based on strong brands and global distribution. Reckitt Benckiser shows exceptional quality (ROE 48.02%, gross margin 59.57%) and attractive valuation (P/E 11.17, FCF yield 9.86%), but growth is deeply negative (revenue -8.20%, earnings -30.90%) and financial health is weak (ND/EBITDA 2.61, current ratio 0.59).

Financial health
4.8
Quality / Moat
8.2
Valuation
7.5
Growth
0.9
Dividend
4.8
Momentum
2.6
Risk & Context
8.8

Detailed metrics

Market and fundamental data as of the analysis date.

💵 Valuation
P/E11.17
Fwd P/E13.73
EV/EBITDA11.30
P/B5.54
P/S2.30
PEG2.07
Market cap31.38 B GBP
Enterprise value40.56 B GBP
🏰 Quality and moat
ROIC (approx.)15.6%
Gross margin59.57%
FCF conversion86%
Operating margin18.19%
📈 Profitability and margins
ROE48.02%
ROA7.88%
Net margin21.09%
FCF3.09 B GBP
FCF yield9.86%
🏦 Solvency and liquidity
Total debt10.25 B GBP
Net debt9.38 B GBP
Cash878.0 M GBP
EBITDA3.59 B GBP
Net debt / EBITDA2.61
D/E179.74
Current ratio0.59
Quick ratio0.38
🚀 Growth
Revenue growth-8.20%
Earnings growth-30.90%
EPS (TTM)4.43 GBP
EPS (Fwd)3.60 GBP
💰 Dividend and risk
Dividend yield0.04%
Payout48.6%
Beta0.25
Analyst consensusBuy (19)
Target price62.39 GBP
52-week range36.64 GBP – 65.23 GBP
⚠️ Main risk: The main risk is the sustained contraction in revenue and earnings (-8.20% and -30.90%), which could indicate structural issues in demand for its products, compounded by a balance sheet with net debt of 2.61x EBITDA and low liquidity.
See the full analysis and compare with the rest of the ranking →

Full AI report

Generated automatically from the metrics, the macro context and the company's news.

Reckitt Benckiser is a British multinational consumer goods company that manufactures and sells cleaning, health, and nutrition products under brands such as Lysol, Durex, and Nurofen, with a business model based on strong brands and global distribution. Reckitt Benckiser shows exceptional quality (ROE 48.02%, gross margin 59.57%) and attractive valuation (P/E 11.17, FCF yield 9.86%), but growth is deeply negative (revenue -8.20%, earnings -30.90%) and financial health is weak (ND/EBITDA 2.61, current ratio 0.59).

Score by category

CategoryScore
Financial health4.8
Quality / Moat8.2
Valuation7.5
Growth0.9
Dividend4.8
Momentum2.6
Risk & Context8.8

OVERALL SCORE: 6.1/10

Context and risks

Moderate regulatory and legal exposure in the UK and dependence on global supply chains, although investment in US manufacturing partially mitigates tariff risk.

News considered in the analysis

  • Manufacturing output down in August; investments by Reckitt, Hitachi — Confirma la inversión en manufactura en EE. UU., pero el contexto de producción industrial débil es un lastre moderado.
  • Stocks to Watch Wednesday Recap: Coinbase, Strategy, Intel, Fraser Group — Listado genérico de acciones a vigilar sin información específica sobre Reckitt.
  • Lysol and Mucinex Maker Reckitt Expands U.S. Manufacturing — Expansión de capacidad en EE. UU. refuerza la cadena de suministro y reduce exposición a aranceles, un movimiento estratégico positivo.
  • Mucinex Maker Bets $400 Million More on U.S. Supply Chain — Inversión adicional de 400 millones de dólares en la cadena de suministro estadounidense, mejora la resiliencia y mitiga riesgos arancelarios.
  • How a Costco partner's bankruptcy could benefit its biggest rival — La quiebra de un socio de Costco podría beneficiar a un rival, posiblemente Reckitt, al ganar espacio en el canal de ventas.

Verdict: Hold; quality and valuation provide support, but lack of growth and leverage limit upside potential in the short term.

Main risk: The main risk is the sustained contraction in revenue and earnings (-8.20% and -30.90%), which could indicate structural issues in demand for its products, compounded by a balance sheet with net debt of 2.61x EBITDA and low liquidity.

Other Consumer Defensive companies

Neighbours in the sector ranking, to compare without going back to the index.

See all 1,000+ companies in the index →

Automatically generated analysis from fundamental, market and news data. Not personalised financial advice — a research tool, not an individual recommendation. Past performance does not guarantee future results. Last update of this analysis: 2026-09-28. Legal notice, privacy & cookies.